Register Login

PLASTIC RECONSTRUCTIVE AND REGENERATIVE SURGERY

Original article

Vol. 23 No. 5 (2025): Blood Transfusion 5-2025 (September-October)

Effectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease

Authors

Arnau Torrent-Rodríguez , Thais Lizondo López , Paola Charry , Maria Suárez-Lledó , Maria Margalida Mestre Ribot , Cristina Cremades Artacho , Maria Queralt Salas , Carmen Martínez Muñoz , Montserrat Rovira , Francesc Fernández-Avilés , Carmen López-Cabezas , Laura Aranda-Cortés , Joan Cid , Miquel Lozano

Key words: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mouth Ulcer, Platelet-Rich Plasma, Regenerative Medicine
Doi: 10.2450/BloodTransfus.880
Cellular therapy and regenerative medicine
Publication Date: 2025-01-13

Abstract

Background - Chronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality of life and often require long-term treatment. Existing therapies provide limited relief, prompting the exploration of new approaches, including the use of autologous platelet lysate (PL) gel for its regenerative properties.

Materials and methods - This observational study evaluated the effectiveness and safety of a topical autologous PL gel in treating oral ulcers associated with cGvHD in seven patients who had undergone allo-HSCT for hematological malignancies. The PL gel was prepared by mixing autologous PL with a gel base under aseptic conditions, and patients applied the gel three times daily. Clinical assessments, including the severity of oral damage and pain levels, were conducted using the NIH-CTCAE scale.

Results - Of the seven patients treated, five completed the study with a median follow-up of 20 months. Significant reductions in oral damage severity and pain levels were observed, with a p-value of 0.0495 for symptom severity and 0.0196 for pain reduction. The average adherence rate was 81.4%, and no adverse effects were reported.

Discussion - The study demonstrated that autologous PL gel is a promising and well-tolerated treatment for oral manifestations of cGvHD, offering significant symptom relief. Despite the small sample size, these findings align with previous studies and support further research into PL gel as a therapeutic option in cGvHD management.

References

Downloads

pdf
Authors

Arnau Torrent-Rodríguez Pharmacy Service, Department of Medicines, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Thais Lizondo López Pharmacy Service, Department of Medicines, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Paola Charry Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Maria Suárez-Lledó Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Maria Margalida Mestre Ribot Pharmacy Service, Department of Medicines, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Cristina Cremades Artacho Pharmacy Service, Department of Medicines, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Maria Queralt Salas Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Carmen Martínez Muñoz Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Montserrat Rovira Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Francesc Fernández-Avilés Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Carmen López-Cabezas Pharmacy Service, Department of Medicines, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Laura Aranda-Cortés Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Joan Cid Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

Miquel Lozano Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari de Barcelona, Barcelona, Spain

  • Abstract viewed - 1231 times
  • pdf downloaded - 0 times